ARVNMEDIUM SIGNALFINANCIAL10-K

ARVN showed significant operational improvement with net losses declining 59% from $198.9M to $80.8M, while maintaining strong liquidity with cash increasing 42% to $142.9M.

The substantial reduction in losses coupled with improved cash position suggests better expense management and potential progress in their development programs. However, the company still faces execution risks around their Pfizer collaboration for vepdegestrant and lacks any approved products for commercialization.

Comparing 2026-02-24 vs 2025-02-11View on EDGAR →
FINANCIAL ANALYSIS

ARVN's financials reflect a company in transition with mixed signals - while net losses improved dramatically by 59% and cash reserves grew 42% to $142.9M, total assets declined 34% and stockholders' equity fell 23%. The significant reduction in total liabilities (46%) and current liabilities (38%) suggests debt restructuring or settlement activities, while the improved operating performance indicates better cost discipline. Overall, the financial picture shows a biotech company that has stabilized its cash burn and strengthened its balance sheet, though still operating at substantial losses typical for pre-revenue biotechnology firms.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-82.5%
$5.7M→$1.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Net Income
P&L
+59.4%
-$198.9M→-$80.8M

Net income grew 59.4% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+52.6%
-$250.2M→-$118.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
-46.4%
$529.7M→$284.0M

Liabilities reduced 46.4% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
+42.2%
$100.5M→$142.9M

Cash position surged 42.2% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
-38%
$229.8M→$142.5M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-34.3%
$1.1B→$700.7M

Current assets declined 34.3% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-34.2%
$1.1B→$717.9M

Total assets contracted 34.2% — asset sales, write-downs, or balance sheet optimization underway.

Total Debt
Balance Sheet
-25%
$800K→$600K

Debt reduced 25% — deleveraging strengthens balance sheet and reduces financial risk.

Stockholders Equity
Balance Sheet
-22.8%
$561.7M→$433.9M

Equity decreased 22.8% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-11
ADDED
You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that we may not actually achieve the 3 plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Our net losses totaled $80.8 million, $198.9 million and $367.3 million for the years ended December 31, 2025, 2024, and 2023, respectively.
We do not have any product candidates that have been approved for commercialization.
We have an ongoing collaboration with Pfizer related to vepdegestrant, but have announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.
If our collaboration with Pfizer or another party is not successful, we may not be able to capitalize on the market potential of vepdegestrant.
We rely on third-part y CMOs or CDMOs for the manufacture and testing of both drug substance and finished drug product for our product can didates for preclinical testing and clinical trials and expect to continue to do so for commercialization.
5 Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and our failure or the failure of our collaborators,CROs, CDMOs, contractors, consultants and other third parties to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
Overview We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.
Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body s ow n natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
We believe that our targeted protein degradation approach is a novel therapeutic modality that may provide distinct advantages over existing therapies and address a broad range of targets, including historically undruggable proteins, in areas of significant unmet need.
REMOVED
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our future results may differ materially from what we expect.
Our net losses totaled $198.9 million, $367.3 million and $282.5 million for the years ended December 31, 2024, 2023, and 2022, respectively.
We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the U.S.
Food and Drug Administration, or FDA, or similar regulatory authorities outside the United States will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs.
We may seek to establish additional collaborations or out-license the development of our product candidates.
If we are not able to establish collaborations or enter into these out-licenses on commercially reasonable terms, we may have to alter our business development plans or product development and commercialization plans.
We rely on third-party CMOs for the manufacture and testing of both drug substance and finished drug product for our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization.
Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
Overview, Programs and Pipeline We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →